









1rchives of Cardiovascular Disease (2014) 107, 406—414




ffective  diagnosis  and  treatment  of
ulmonary  embolism:  Improving  patient
utcomes
es  changements  dans  le  diagnostic  et  la  thérapeutique  pour
méliorer  le  pronostic  de  l’embolie  pulmonaire
Guy  Meyera,b,∗
a Division  of  respiratory  and  intensive  care,  hôpital  européen  Georges-Pompidou,  20,  rue
Leblanc, 75015  Paris,  France
b Université  Paris  Descartes,  Sorbonne  Paris  Cité,  75006  Paris,  France
Received  4  April  2014;  received  in  revised  form  2  May  2014;  accepted  5  May  2014






Summary  Pulmonary  embolism  can  be  life  threatening  and  difﬁcult  to  diagnose  as  signs
and symptoms  are  not  speciﬁc.  European  guidelines  recommend  stratiﬁcation  of  pulmonary
embolism by  risk  of  early  mortality.  Patients  with  suspected  pulmonary  embolism  should  be
assessed  for  clinical  probability  of  pulmonary  embolism  using  a  validated  risk  score.  A  low
or intermediate  clinical  probability  plus  a  negative  high-sensitivity  D-dimer  test  excludes
pulmonary  embolism.  Anticoagulation  is  indicated  in  patients  with  a  positive  multidetector
computed  tomography  or  high-probability  lung  scan.  An  important  part  of  the  management  of
patients with  pulmonary  embolism  has  traditionally  been  anticoagulant  treatment  with  par-
enteral heparins  and  oral  vitamin  K  antagonists.  Although  effective,  this  dual-drug  approach  is
associated with  limitations.  Direct  oral  anticoagulants  that  may  overcome  some  of  these  prob-
lems have  been  tested  in  phase  III  clinical  trials  for  the  treatment  of  venous  thromboembolism.
Of these,  rivaroxaban  and  apixaban  have  demonstrated  non-inferiority  to  standard  therapy
when given  as  single-drug  approaches  for  venous  thromboembolism  treatment,  and  provided
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signiﬁcant  reductions  in  major  bleeding  rates.  Dabigatran  and  edoxaban  were  non-inferior  to
standard therapy  when  given  as  part  of  a  dual-drug  approach  after  initial  parenteral  antico-
agulation,  and  reduced  clinically  relevant  bleeding  rates.  There  may  be  a  beneﬁt  to  extended
anticoagulation  with  direct  oral  anticoagulants  for  the  prevention  of  recurrent  venous  throm-
boembolism.  Registry  studies  will  provide  more  information  on  the  use  of  these  agents  in
real-world populations.  Accurate  diagnosis  and  risk  stratiﬁcation  of  patients  with  pulmonary
embolism, together  with  simpliﬁed  anticoagulation  therapy,  is  likely  to  improve  outcomes.






Résumé  L’embolie  pulmonaire  est  une  pathologie  potentiellement  létale  et  est  difﬁcile  à
diagnostiquer.  Les  signes  et  les  symptômes  de  l’embolie  pulmonaire  ne  sont  pas  spéciﬁques.
Les recommandations  européennes  recommandent  de  stratiﬁer  les  malades  selon  leur  risque
de mortalité.  La  probabilité  clinique  de  l’embolie  pulmonaire  doit  être  évaluée  à  l’aide  d’un
score devant  toute  suspicion  clinique  d’embolie  pulmonaire.  Une  probabilité  clinique  faible  ou
intermédiaire  associée  à  un  taux  de  D-dimère  normal  élimine  le  diagnostic.  Le  diagnostic  est
afﬁrmé par  l’angioscanner  thoracique  ou  la  scintigraphie  pulmonaire.  Le  traitement  initial  asso-
cie traditionnellement  une  héparinothérapie  parentérale  et  un  antagoniste  de  la  vitamine  K.
Ce traitement  est  efﬁcace  mais  comporte  certains  inconvénients.  Des  inhibiteurs  oraux  directs
de la  coagulation,  qui  pourraient  limiter  ces  inconvénients,  ont  été  testés  dans  de  grands  essais
de phase  III.  Parmi  eux,  le  rivaroxaban  et  l’apixaban  administrés  dès  l’inclusion  ont  démontré
leur non-infériorité  par  rapport  au  traitement  standard  en  termes  d’efﬁcacité  tout  en  obtenant
une réduction  des  hémorragies  majeures.  Le  dabigatran  et  l’edoxaban  sont  également  non
inférieurs au  traitement  standard  après  un  traitement  parentéral  initial  et  sont  également  asso-
ciés à  une  réduction  des  saignements  cliniquement  signiﬁcatifs.  La  prolongation  du  traitement
au-delà de  six  mois  en  cas  de  thrombose  non  provoquée  pourrait  être  associée  à  une  réduc-
tion des  récidives.  Des  études  de  registres  devraient  apporter  des  informations  sur  l’utilisation
de ces  nouvelles  molécules  en  situation  de  soin  courant.  Un  diagnostic  rigoureux,  associé  à
une stratiﬁcation  du  risque  et  à  un  traitement  anticoagulant  simpliﬁé  devraient  permettre  une
amélioration  du  pronostic  de  l’embolie  pulmonaire.


















Pulmonary  embolism  (PE)  is  a  relatively  common  disease,
with  an  incidence  ranging  from  60  to  112  per  100,000  inhabi-
tants  of  the  United  States  [1],  and  is  the  third  most  common
cause  of  death  among  patients  with  cardiovascular  diseases
[2].  Patients  are  at  particular  risk  in  the  acute  stage  of  the
disease,  with  30-day  mortality  rates  in  excess  of  15%  for  PE
associated  with  shock  and/or  hypotension  [3].  PE  is  difﬁ-
cult  to  diagnose  because  of  the  wide  range  of  presentations
of  the  disease.  Among  those  patients  who  die  of  PE,  94%
do  so  before  diagnosis  [4].  The  mainstay  of  treatment  for
most  patients  with  PE  is  anticoagulation,  and  the  risk  of
death  is  much  reduced  in  optimally  anticoagulated  patients.
The  recurrence  rate  of  venous  thromboembolism  (VTE)  after
stopping  anticoagulant  treatment  varies  with  the  cause  of
the  disease  and  is  much  higher  in  patients  with  unprovoked
VTE  than  in  patients  with  VTE  provoked  by  a  major  tran-
sient  risk  factor  [5].  Duration  of  anticoagulant  treatment  is
tailored  to  the  risks  of  VTE  recurrence  and  bleeding  for  each
individual  patient  [3,6].Treatment  of  PE  has  predominantly  involved  the  use
of  low-molecular-weight  heparins  (LMWHs),  unfractionated
heparin  or  fondaparinux  in  combination  with  vitamin  K




Ts  associated  with  some  limitations,  including  the  need  to
o-administer  the  parenteral  agent  and  VKA  concurrently
or  several  days  at  the  start  of  treatment,  and  the  sub-
equent  need  for  regular  coagulation  monitoring  and  dose
djustments  during  VKA  monotherapy.  The  recently  devel-
ped  direct  oral  anticoagulants  circumvent  some  of  these
imitations,  and  several  have  completed  large  phase  III  clin-
cal  trials  in  the  treatment  of  acute  VTE.  In  Europe,  only
ivaroxaban  is  currently  approved  for  the  treatment  and  sec-
ndary  prevention  of  deep  vein  thrombosis  (DVT)  and  PE.  In
he  USA,  rivaroxaban  and,  more  recently,  dabigatran  have
een  approved  for  VTE  treatment.
This  review  covers  the  diagnosis  and  treatment  of  PE,
ocusing  on  data  for  direct  oral  anticoagulants.
linical presentations of PE
ost  patients  with  suspected  PE  present  with  some  degree
f  chest  pain  and  dyspnoea,  a  frequent  cause  of  refer-
al  to  the  emergency  department.  These  symptoms  are
on-speciﬁc  and  can  be  confused  with  other  differential
iagnoses,  such  as  acute  coronary  syndromes,  exacerbation
f  chronic  obstructive  pulmonary  disease  or  pneumonia  [7].







































































































ain—are  encountered  in  only  up  to  10%  and  42%  of  patients
ith  PE,  respectively  [8,9].  In  the  most  severe  cases  of
E,  patients  may  present  with  shock  and/or  haemodynamic
nstability  [3].  The  lack  of  speciﬁc  symptoms  and  the  pres-
nce  of  underlying  disease  in  a  signiﬁcant  proportion  of
atients  with  PE  probably  explain  the  signiﬁcant  diagnostic
elay  observed  in  some  cases.
isk stratiﬁcation for suspected PE
isk  stratiﬁcation  is  a  relatively  new  concept  in  the  ﬁeld
f  PE.  The  size  of  the  emboli  and  degree  of  vessel  occlu-
ion  do  not  accurately  describe  the  risk  of  death  of  a
atient  with  suspected  PE,  and  the  terms  ‘massive’  and
sub-massive’  are  misleading  [3].  Therefore,  other  methods
re  required  to  assess  mortality  risk  and  inform  manage-
ent  decisions.  Accordingly,  the  guidelines  of  the  European
ociety  of  Cardiology  categorize  patients  presenting  with
uspected  PE  by  their  predicted  risk  of  early  mortality.
atients  are  divided  into  high-risk  or  non-high-risk  (which  is
urther  divided  into  intermediate-  and  low-risk)  categories
ased  on  the  presence  of  shock,  myocardial  injury  and  right
entricular  dysfunction  detected  by  echocardiography  and
ardiac  biomarkers  [3].  The  risk  category  to  which  a  patient
s  assigned  informs  the  approach,  whether  it  be  emergency
hrombolysis  or  embolectomy  (high-risk:  >  15%  early  mortal-
ty  risk)  or  further  conﬁrmatory  diagnostic  steps  and,  if  PE
s  conﬁrmed,  management  with  anticoagulants  (non-high-
isk:  <  1—15%  early  mortality  risk)  [3].  Risk  stratiﬁcation  also
llows  for  the  selection  of  patients  who  may  be  suitable  for
utpatient  anticoagulant  treatment  [10].
The  Pulmonary  Embolism  Severity  Index  is  a  clinical  tool
esigned  to  assess  the  risk  of  death  in  patients  with  PE.
ccording  to  this,  patients  with  PE  can  be  divided  into  ﬁve
roups  with  different  outcomes.  The  30-day  risk  of  death  in
atients  belonging  to  the  low-risk  categories  I  and  II  is  usu-
lly  <  3%,  whereas  that  in  patients  belonging  to  the  high-risk
ategory  V  varies  between  10%  and  25%  [11,12].  A  simpli-
ed  version  of  the  rule,  based  on  six  variables  that  all  carry
he  same  weight  (one  of  which  is  a  composite  of  two  origi-
al  variables),  has  been  shown  to  have  the  same  sensitivity
nd  speciﬁcity  as  the  original  [13].  Right  ventricular  dilata-
ion  on  echocardiography  or  computed  tomography  (CT)
ulmonary  angiography,  and  right  ventricular  dysfunction  or
njury  detected  by  brain  natriuretic  peptide  and  troponin
esting,  allow  further  risk  stratiﬁcation  of  clinically  stable
atients  with  PE  [14].
onﬁrmatory diagnosis in suspected
igh-risk PE
n  patients  with  suspected  high-risk  PE,  CT  pulmonary
ngiography  is  the  preferred  technique  to  conﬁrm  the  diag-
osis  (Fig.  1)  [3].  Echocardiography  is  an  alternative  if  CT
ulmonary  angiography  is  unavailable  or  the  patient  is  too
nstable.  In  haemodynamically  unstable  patients,  acute  pul-
onary  hypertension  and  right  ventricular  overload  seen  on





r  embolectomy,  particularly  when  other  tests  cannot  be
erformed  (Fig.  1) [3].
onﬁrmatory diagnosis in suspected
on-high-risk PE
f  a  diagnosis  of  non-high-risk  PE  is  suspected,  the  ﬁrst  step
s  to  assess  the  clinical  probability  of  PE  using  a  standard-
zed  clinical  prediction  rule  (Fig.  1)  [3].  According  to  the
esult,  patients  can  be  divided  into  three  (low,  interme-
iate  or  high  probability  of  PE)  or  two  (‘PE  unlikely’  and
PE  likely’)  groups,  each  with  different  probabilities  of  PE.
 negative  result  from  a  high-sensitivity  D-dimer  test  in
atients  with  either  low—intermediate  probability  or  ‘PE
nlikely’  safely  excluded  PE  in  about  30%  of  outpatients  pre-
enting  to  seven  Dutch  hospitals  with  suspected  PE  [15].  In
atients  with  either  a  high  clinical  probability  or  an  elevated
-dimer  plasma  concentration,  three  options  for  conﬁrma-
ory  diagnosis  are  available:  CT  pulmonary  angiography,
entilation—perfusion  lung  scanning  or  venous  compression
ltrasound  [3].
Nowadays,  multidetector  spiral  CT  pulmonary  angiog-
aphy  is  considered  the  standard  option  for  conﬁrming
on-high-risk  PE  (Fig.  1).  Using  multidetector  spiral  CT  pul-
onary  angiography,  the  rate  of  recurrent  VTE  within  3
onths  after  a negative  examination  has  been  reported  to
e  as  low  as  0.3%  with  or  without  additional  ultrasound,
onﬁrming  a  high  sensitivity  [16].  Compared  with  single-
etector  CT  pulmonary  angiography  and  the  ﬁrst  generation
f  multidetector  devices,  the  recent  64-detector  systems
etect  a  higher  rate  of  isolated  subsegmental  PEs,  the  clin-
cal  signiﬁcance  of  which  has  been  questioned  [17].
Ventilation—perfusion  lung  scanning  has  been  used  to
iagnose  PE  for  many  years.  A  normal  ventilation—perfusion
ung  scan  virtually  eliminates  the  diagnosis  of  PE,  but  about
0%  of  examinations  are  non-diagnostic  and  do  not  by  them-
elves  allow  exclusion  or  conﬁrmation  of  the  diagnosis  of  PE
18]. On  the  other  hand,  a  high-probability  scan  is  strongly
orrelated  with  a  diagnosis  of  PE,  but  further  tests  may  be
onsidered  in  patients  with  a  low  clinical  probability  risk
core  [3].
Compression  ultrasound  allows  diagnosis  of  DVT  in
atients  with  clinically  suspected  PE,  and  the  ﬁnding  of  a
roximal  DVT  in  a  patient  with  clinically  suspected  PE  is
ccepted  as  a  surrogate  for  the  diagnosis  of  PE  and  does  not
eed  to  be  conﬁrmed  by  an  examination  of  the  chest  [3].
owever,  a  normal  proximal  compression  ultrasound  does
ot  exclude  the  diagnosis  of  PE  [19],  and  only  10%  of  exami-
ations  are  positive  in  patients  with  suspected  PE  [20].  Thus,
ompression  ultrasound  cannot  be  considered  an  efﬁcient
iagnostic  method  for  most  patients  with  suspected  PE.
urrent treatment options for PE
n  the  relatively  few  patients  with  high-risk  PE  (presence
f  shock  and/or  hypotension),  thrombolytic  therapy  is  rec-
mmended.  In  cases  where  thrombolytic  therapy  fails  or
s  contraindicated,  catheter-assisted  thrombus  removal  or
urgical  embolectomy  provides  a back-up  option  [3,6].  Such
atients  should  also  receive  immediate  anticoagulation  with
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Figure 1. Recommended diagnostic pathway for patients with suspected PE—European Society of Cardiology guidelines 2008 [3]. Notes:
CT is deﬁned as not immediately available if the patient’s critical condition allows only bedside diagnostic tests. Conﬁrmation of DVT via
compression venous ultrasound may also assist with clinical decisions. CT is considered diagnostic of PE if the most proximal thrombus is
at least segmental. If single-detector CT is negative, a negative proximal lower limb venous ultrasound is required to safely exclude PE.
If MDCT is negative in patients with a high clinical probability of PE, further investigations may be considered. CT: computed tomography;
CTPA: computed tomography pulmonary angiography; DVT: deep vein thrombosis; echoCG: echocardiography; MDCT: multidetector spiral













munfractionated  heparin  with  haemodynamic  and  respira-
tory  support  as  required.  Anticoagulation  is  the  mainstay
treatment  option  for  haemodynamically  stable  patients  with
non-high-risk  PE  and  should  be  started  as  soon  as  the  diag-
nosis  is  suspected,  at  least  in  patients  with  a  high  clinical
probability  of  PE  and  no  contraindication  to  anticoagulant
therapy  [3,6].
Traditional anticoagulants for the treatment
of PE
The  traditional  parenteral  anticoagulants  employed  in
the  initial  treatment  of  non-high-risk  PE  include  LMWH,
intravenous  or  subcutaneous  unfractionated  heparin  or  fon-
daparinux.  Except  for  patients  with  VTE  and  cancer,  LMWH
is  normally  given  for  the  ﬁrst  5—7  days  of  treatment  and  is




ontil  the  international  normalized  ratio  reaches  between
.0  and  3.0  [3,6]. Owing  to  their  slow  onset  of  action,
KAs  must  initially  be  used  in  conjunction  with  the  faster-
cting  parenteral  anticoagulants.  During  treatment  with  a
KA,  patients  require  frequent  coagulation  monitoring  to
aintain  treatment  within  a  therapeutic  range  (interna-
ional  normalized  ratio  2.0—3.0).  The  initial  dosage  varies
reatly  between  patients  and,  because  of  drug  and  food
nteractions,  the  subsequent  dosage  may  vary  according  to
hanges  in  associated  treatment  and  diet.  Even  under  con-
rolled  conditions,  the  time  in  the  therapeutic  range  usually
oes  not  exceed  65%  [21—24]. VKAs  represent  one  of  the
ost  frequent  causes  of  referral  to  emergency  departments
ecause  of  adverse  drug  reactions,  especially  in  the  elderly
25]. These  limitations  underscore  the  need  for  simpler

















































































































irect oral thrombin and Factor Xa inhibitors
or the treatment of PE
 series  of  novel  anticoagulant  drugs  have  recently  been
eveloped.  These  drugs  are  direct  inhibitors  of  Factor  IIa
thrombin)  or  Factor  Xa,  are  not  subject  to  food  interac-
ions  and  have  minimal  drug  interactions  compared  with
KAs.  They  can  be  administered  orally  at  a  ﬁxed  dosage
ithout  the  need  for  routine  coagulation  monitoring  [26].
mong  these  drugs,  rivaroxaban,  dabigatran,  apixaban  and
doxaban  have  been  tested  for  the  initial  and/or  secondary
revention  of  VTE  in  large  phase  III  studies  [21—24,27—30].
n  2012,  rivaroxaban  became  the  ﬁrst  direct  oral  antico-
gulant  to  be  approved  for  the  treatment  of  DVT  and  PE
nd  the  prevention  of  recurrent  VTE  [31,32].  In  contrast  to
he  combination  of  LMWH  and  VKA,  rivaroxaban  provides  a
xed-dose,  single-drug  approach  to  the  initial  and  contin-
ed  treatment  of  PE  in  patients  who  are  haemodynamically
table  and  do  not  require  thrombolysis  or  embolectomy.
hase III studies of the direct oral
nticoagulants in the treatment of acute
TE
he  EINSTEIN  PE  study  was  an  open-label,  randomized,
on-inferiority  study  that  compared  oral  rivaroxaban  with
tandard  therapy  in  patients  with  acute,  symptomatic  PE
ith  or  without  DVT  [23].  Among  other  criteria,  patients
ere  excluded  if  they  had  haemodynamic  instability,  cre-
tinine  clearance  (CrCl)  <  30  mL/min,  clinically  signiﬁcant
iver  disease,  had  received  therapeutic  parenteral  anti-
oagulation  for  >  48  hours,  or  more  than  a  single  dose  of
 VKA  before  randomization.  Rivaroxaban  was  given  at  a
ose  of  15  mg  twice  daily  for  the  ﬁrst  3  weeks  followed
y  20  mg  once  daily.  Standard  therapy  was  subcutaneous
noxaparin  1.0  mg/kg  twice  daily  followed  by  either  war-
arin  or  acenocoumarol  for  3,  6  or  12  months.  A  total
f  2419  patients  were  assigned  to  rivaroxaban  and  2413
o  standard  therapy.  Recurrent  VTE  occurred  in  2.1%  of
atients  who  were  given  rivaroxaban  compared  with  1.8%
ho  received  standard  therapy  (P  =  0.003  for  non-inferiority;
ig.  2).  Major  or  non-major  clinically  relevant  bleeding
ccurred  in  10.3%  and  11.4%  of  patients,  respectively  (haz-
rd  ratio  [HR]  0.90,  95%  conﬁdence  interval  [CI]  0.76—1.07;
 =  0.23;  Fig.  2).  Major  bleeding  occurred  in  1.1%  and
.2%  of  patients,  respectively  (HR  0.49,  95%  CI  0.31—0.79;
 =  0.003),  representing  a  51%  relative  risk  reduction  (Fig.  2)
23].  Subgroup  analysis  demonstrated  that  rates  of  recur-
ent  VTE  and  bleeding  were  similar  in  both  treatment  groups
egardless  of  age,  weight,  sex,  renal  function  or  extent  of
E.
The  EINSTEIN  DVT  study  enrolled  patients  with  acute,
ymptomatic  proximal  DVT  without  symptomatic  PE  [22].
eneral  exclusion  criteria  were  similar  to  those  applied
n  EINSTEIN  PE.  As  in  EINSTEIN  PE,  rivaroxaban  was  non-
nferior  to  standard  therapy  (P  <  0.001  for  non-inferiority)
22].  Major  or  non-major  clinically  relevant  bleeding  and
ajor  bleeding  alone  occurred  with  similar  incidences  in
oth  treatment  groups  [22].  In  a  pooled  analysis  of  EIN-





o  standard  therapy  for  efﬁcacy  and  led  to  a  46%  relative
isk  reduction  in  major  bleeding  (Fig.  3) [33].  Rivaroxa-
an  was  associated  with  a  signiﬁcant  improvement  in  net
linical  beneﬁt  (deﬁned  as  the  composite  incidence  of  recur-
ent  VTE  and  major  bleeding)  in  fragile  patients  (age  > 75
ears,  CrCl  <  50  mL/min  or  weight  ≤  50  kg;  HR  0.51,  95%  CI
.34—0.77),  primarily  as  a  result  of  a  63%  relative  risk  reduc-
ion  in  major  bleeding  in  this  group  compared  with  standard
herapy  [33].
AMPLIFY  (Apixaban  for  the  Initial  Management  of  Pul-
onary  Embolism  and  Deep-Vein  Thrombosis  as  First-line
herapy)  was  a  randomized,  double-blind  study  comparing
pixaban  (10  mg  twice  daily  for  7  days  followed  by  5  mg
wice  daily  for  6  months)  with  conventional  therapy  (subcu-
aneous  enoxaparin  followed  by  warfarin)  in  5395  patients
ith  acute  VTE  [24]. Reasons  for  ineligibility  included  con-
raindications  to  standard  anticoagulant  therapy,  cancer,
rovoked  thrombosis  without  a  persistent  risk  factor  for
ecurrence,  if  <  6  months  of  treatment  was  planned,  treat-
ent  with  >  165  mg  aspirin  daily  or  CrCl  <  25  mL/min.  No
ore  than  two  doses  of  once-daily  LMWH,  fondaparinux  or
KA;  three  doses  of  twice-daily  LMWH;  or  >  36  hours  of  con-
inuous  intravenous  heparin  were  permitted.  Apixaban  was
on-inferior  to  standard  therapy  for  the  primary  efﬁcacy
utcome  of  recurrent  symptomatic  VTE  or  VTE-related  death
P  <  0.001  for  non-inferiority),  with  a  69%  relative  risk  reduc-
ion  in  major  bleeding  (Fig.  3)  [24].  Outcomes  in  subgroups,
ncluding  elderly  patients  and  those  weighing  >  100  kg  were
onsistent  with  the  overall  population.
RE-COVER  was  a double-blind,  randomized  trial  that  com-
ared  6  months  of  treatment  with  dabigatran  (ﬁxed  dose
f  150  mg  twice  daily)  with  dose-adjusted  warfarin  ther-
py  in  patients  with  proximal  DVT  or  PE  [21].  Patients  were
xcluded  for  reasons  of  haemodynamic  instability,  symptoms
asting  > 14  days,  recent  unstable  cardiovascular  disease,
igh  bleeding  risk,  clinically  signiﬁcant  liver  disease,
rCl  <  30  mL/min,  or  a  requirement  for  aspirin  >  100  mg/day.
ll  patients  were  initially  given  an  approved  parenteral
nticoagulant  (generally  unfractionated  heparin  or  LMWH).
abigatran  was  non-inferior  to  standard  therapy  for  the  pre-
ention  of  recurrent  VTE  (P  <  0.001  for  non-inferiority),  with
 signiﬁcant  reduction  in  clinically  relevant  bleeding  but
ot  major  bleeding  (Fig.  3)  [21].  Outcomes  were  consistent
egardless  of  variations  in  demographic  factors.  The  RE-
OVER  II  study  had  essentially  the  same  design  as  RE-COVER
nd  the  results,  recently  published,  support  the  outcomes
f  RE-COVER  [27].
Edoxaban  was  compared  with  warfarin  in  the  Hokusai-
TE  study,  a  randomized,  double-blind,  non-inferiority  study
f  8292  patients  with  VTE  [30]. Patients  were  excluded  if
hey  had  contraindications  to  standard  anticoagulant  treat-
ent,  had  received  >  48  hours  of  heparin  treatment  or  more
han  one  dose  of  VKA,  had  cancer  with  anticipated  long-
erm  LMWH  treatment,  were  receiving  aspirin  >  100  mg/day
r  dual  antiplatelet  therapy,  or  had  CrCl  <  30  mL/min.  As
ith  dabigatran,  treatment  with  edoxaban  (60  mg  once  daily
r  30  mg  once  daily  in  patients  with  CrCl  30—50  mL/min
r  weight  ≤  60  kg  or  who  were  receiving  treatment  with
otent  P-glycoprotein  inhibitors)  was  initiated  after  initial
arenteral  anticoagulation  [30]. Edoxaban  was  non-inferior
o  standard  therapy  for  the  prevention  of  symptomatic
ecurrent  VTE  (P  <  0.001  for  non-inferiority)  [30].  Clinically
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Figure 2. Primary efﬁcacy, safety and net clinical beneﬁt outcomes in patients with PE with or without DVT in the phase III EINSTEIN
PE study of single-drug rivaroxaban compared with standard therapy (enoxaparin/VKA). Efﬁcacy endpoints (recurrent VTE and net clinical
beneﬁt) were evaluated in the intention-to-treat population. Bleeding outcomes were evaluated in the safety population. Net clinical beneﬁt
was deﬁned as the composite incidence of recurrent VTE and major bleeding. Clinically relevant bleeding was deﬁned as the composite
of major and non-major clinically relevant bleeding. CI: conﬁdence interval; DVT: deep vein thrombosis; PE: pulmonary embolism; VKA:
vitamin K antagonist; VTE: venous thromboembolism.
Figure 3. Published, phase III clinical studies of direct oral anticoagulants for the treatment of acute venous thromboembolism














































elevant  bleeding  was  signiﬁcantly  reduced  with  edoxaban,
ut  major  bleeding  was  not  (Fig.  3)  [30].  Efﬁcacy  with
doxaban  was  also  conﬁrmed  in  a  subset  of  patients  with
evere  PE  (N-terminal  prohormone  of  brain  natriuretic  pep-
ide  level  ≥  500  pg/mL)  [30].
econdary prevention of VTE with direct
ral anticoagulants
atients  with  unprovoked  PE  (i.e.  occurring  in  the  absence
f  a  major  risk  factor  such  as  trauma,  surgery,  immobiliza-
ion  or  cancer)  have  a  high  risk  of  recurrent  VTE  after  the
nd  of  anticoagulant  treatment  [5].  Approximately  5—10%
f  these  patients  will  have  a  recurrent  event  during  the  ﬁrst
ear  after  a  3-  or  6-month  course  of  anticoagulant  ther-
py,  and  about  30%  of  them  will  have  a  recurrence  within
 years  [34].  Dabigatran,  rivaroxaban  and  apixaban  have
een  investigated  for  the  prevention  of  these  recurrent
vents.  Dabigatran  and  rivaroxaban  were  administered  using
 single-dose  regimen  (150  mg  twice  daily  for  dabigatran  and
0  mg  once  daily  for  rivaroxaban),  whereas  apixaban  was
iven  at  two  different  doses  of  2.5  mg  and  5  mg  twice  daily
22,28,29].  The  three  drugs  achieved  a  relative  risk  reduc-
ion  of  recurrent  VTE  compared  with  placebo  of  64—92%





igure 4. Published phase III clinical studies of direct oral anticoagula
P = 1.0. bid: twice daily; CI: conﬁdence interval; OAC: oral anticoagulanG.  Meyer
ncrease  in  major  plus  non-major  clinically  relevant  bleed-
ng  with  rivaroxaban  and  dabigatran,  although  not  apixaban,
ut  without  a  signiﬁcant  increase  in  major  bleeding  for  any
gent.  The  net  increase  in  major  bleeding  did  not  exceed
%,  whereas  the  net  decrease  in  recurrent  VTE  (plus  or
inus  VTE-related  or  all-cause  mortality,  depending  on  the
tudy)  varied  from  5.2%  to  7.8%  [22,28,29]. Only  dabiga-
ran  has  been  compared  with  warfarin  for  the  secondary
revention  of  VTE  [28].  The  two  treatments  were  equally
fﬁcacious  for  the  prevention  of  recurrent  VTE  (P  =  0.01
or  non-inferiority)  and  the  incidence  of  major  bleeding
as  similar  (HR  0.52,  95%  CI  0.27—1.02).  Dabigatran  was
ssociated  with  an  increase  in  the  rate  of  acute  coronary
yndromes  (0.9%  vs  0.2%;  P  =  0.02)  [28].
iscussion
revious  results  in  patients  with  VTE  explain  why,  in  phase
II  trials,  dabigatran  and  edoxaban  were  started  only  after  a
tandard  course  of  parenteral  treatment  with  LMWH,  and
hy  rivaroxaban  and  apixaban  were  started  immediately
fter  randomization,  but  at  a  higher  dosage  during  the  acute
reatment  phase.  These  treatment  schedules  were  selected
o  optimize  the  efﬁcacy  of  the  direct  oral  anticoagulant  regi-
ens  during  the  initial  period  of  treatment  where  the  risk
f  recurrent  VTE  is  high.  Previous  experience  with  ximela-
nts for the prolonged treatment of acute VTE [22,28,29]. aP = 0.11.
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gatran  and  idraparinux,  which  were  the  ﬁrst  drugs  designed
to  challenge  the  usual  combination  of  heparin  or  fonda-
parinux  and  warfarin,  suggested  a  higher  risk  of  recurrent
VTE  with  the  new  compounds  during  the  ﬁrst  month  of
therapy  [35,36].  These  results,  and  those  of  other  stud-
ies,  highlight  the  need  for  a  highly  effective  anticoagulation
regimen  early  in  the  course  of  VTE.
The  results  of  clinical  studies  of  direct  oral  anticoagu-
lants  were  obtained  in  selected  patients  who  were  relatively
young  and  had  few  associated  diseases,  but  at  least  for
rivaroxaban  [22,23]  and  edoxaban  [30],  the  results  also
apply  for  important  subgroups  of  PE  patients.  Additionally,
the  VKA  time  in  therapeutic  range  was  potentially  higher  in
these  studies  than  in  real  life,  and  so  VKAs  can  be  consid-
ered  to  have  been  given  optimally  in  these  trials.  Therefore,
the  observed  beneﬁts  of  the  direct  oral  anticoagulants  may
be  more  pronounced  in  routine  clinical  practice  than  in  the
study  settings.  Several  registries  and  real-world  studies  are
underway  or  planned  to  investigate  the  epidemiology  and
treatment  outcomes  of  VTE  encountered  in  daily  clinical
practice,  including  in  groups  of  patients  who  would  nor-
mally  be  excluded  from  clinical  trials.  Established  registries
include  the  Registro  Informatizado  de  Pacientes  con  Enfer-
medad  TromboEmbólica  (RIETE),  which  has  recruited  more
than  39,000  patients  since  its  inception  in  2001  and  has,
among  other  important  data,  provided  predictive  variables
for  major  bleeding  events  in  patients  who  present  with  acute
VTE  [37].
More  recently,  two  registries  have  been  created  to  look
speciﬁcally  at  patterns  of  treatment  and  outcomes  in  acute
and  long-term  management  of  VTE  with  direct  oral  anticoag-
ulants.  The  Dresden  Registry  aims  to  recruit  2000  unselected
adult  patients  in  Germany  (http://www.noac-register.de/),
and  the  Global  Anticoagulant  Registry  in  the  FIELD
(GARFIELD)  VTE  registry  will  include  patients  in  more  than
20  countries  (http://www.tri-london.ac.uk/garﬁeld-vte).
Conclusions
Accurate  diagnosis  and  risk  stratiﬁcation  of  patients  with
PE,  together  with  the  simpliﬁed  treatment  that  the  direct
oral  anticoagulants  can  provide,  are  likely  to  improve
patient  outcomes  and  reduce  mortality  associated  with  this
disease.
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